Northwire Canada EditionSaturday, October 17, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0% GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0%

Healthcare

Page 67
  1. Feb 02, 2026 · 08:00 · NURS

    Hydreight Technologies Issues Fiscal 2026 Revenue Guidance of = $150 Million and Provides Q1 2026 Outlook

    Hydreight Technologies Issues Fiscal 2026 Revenue Guidance of = $150 Million and Provides Q1 2026 Outlook

    01
  2. Feb 02, 2026 · 08:00 · VST

    Hydreight Technologies Issues Fiscal 2026 Revenue Guidance of = $150 Million and Provides Q1 2026 Outlook

    Hydreight Technologies Issues Fiscal 2026 Revenue Guidance of = $150 Million and Provides Q1 2026 Outlook

    02
  3. Feb 02, 2026 · 07:03 · TLT

    Theralase(R) Completes Enrollment in Bladder Cancer Clinical Study

    Theralase(R) Completes Enrollment in Bladder Cancer Clinical Study

    03
  4. Feb 02, 2026 · 07:00 · DR

    Medical Facilities Corporation Announces Sale of Oklahoma Spine Hospital, LLC and The Surgery Center of Newport Coast, LLC

    Medical Facilities Corporation Announces Sale of Oklahoma Spine Hospital, LLC and The Surgery Center of Newport Coast, LLC

    04
  5. Feb 02, 2026 · 07:00 · NLH

    Nova Leap Health Corp. Launches Palliative Care Division In Nova Scotia Through Earth Angels Home Care

    Nova Leap Health Corp. Launches Palliative Care Division In Nova Scotia Through Earth Angels Home Care

    05
  6. Feb 02, 2026 · 03:06 · SEGN

    Seegnal prescription platform used by Israeli hospital

    Seegnal prescription platform used by Israeli hospital

    06
  7. Jan 30, 2026 · 18:55 · OTC

    Ocumetics seeks TSX-V OK for forbearance agreement

    Ocumetics seeks TSX-V OK for forbearance agreement

    07
  8. Jan 30, 2026 · 16:26 · METX

    ME Therapeutics talks pipeline and in vivo CAR plans

    ME Therapeutics talks pipeline and in vivo CAR plans

    08
  9. Jan 30, 2026 · 08:00 · 4151

    Kyowa Kirin to Regain Control of Rocatinlimab Development and Commercialization Program, Demonstrating Strong Commitment to Address High Unmet Medical Need in Atopic Dermatitis

    Kyowa Kirin to Regain Control of Rocatinlimab Development and Commercialization Program, Demonstrating Strong Commitment to Address High Unmet Medical Need in Atopic Dermatitis

    09
  10. Jan 29, 2026 · 18:00 · 4875

    MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN-166 (ibudilast) in ALS patients

    MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN-166 (ibudilast) in ALS patients

    10
  11. Jan 29, 2026 · 18:00 · SKNY

    LIR Life Sciences Reports Positive Interim Preclinical Results from Comparative Animal Study of Novel CPP-Enabled Transdermal Delivery of GLP/GIP-Based Therapies

    LIR Life Sciences Reports Positive Interim Preclinical Results from Comparative Animal Study of Novel CPP-Enabled Transdermal Delivery of GLP/GIP-Based Therapies

    11
  12. Jan 29, 2026 · 08:00 · BIOV

    BioVaxys Reports Positive Phase 2 Data for Maveropepimut (MVP-S) + Pembrolizumab and Low-Dose Cyclophosphamide in Metastatic Bladder Cancer

    BioVaxys Reports Positive Phase 2 Data for Maveropepimut (MVP-S) + Pembrolizumab and Low-Dose Cyclophosphamide in Metastatic Bladder Cancer

    12
  13. Jan 28, 2026 · 18:24 · DTC

    Defence, Cdn Nuclear Laboratories expand work program

    Defence, Cdn Nuclear Laboratories expand work program

    13
  14. Jan 28, 2026 · 18:09 · AIAI

    Netramark closes $3.11M first tranche of financing

    Netramark closes $3.11M first tranche of financing

    14
← Newer Older →